Alpelisib in PIK3CA-related overgrowth syndrome

Alpelisib in PIK3CA-related overgrowth syndrome

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is now recruiting. Learn more about enrolling here.

Description

The purpose of this study is to find out if alpelisib (BYL719;the “study drug”), is safe and effective (can help) people who have PIK3CA-related overgrowth spectrum (PROS) disease. 

Eligibility and criteria
IRB Number:
21-018540
Eligible age range:
6 years - 60 years
Clinical trial phase:
Phase II
Official title:
EPIK-P2: A Phase II double-blind study with an upfront, 16- week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)

What to expect
Participation will last for up to 5 years. Subjects will be assigned to take either the study drug or placebo for the first 16 weeks. From week 17 on, subjects will receive study drug. Study visits include the following assessments: blood draws, ECGs, Echocardiograms, tissue collection (if biopsy is performed as standard of care), whole body MRIs, x-rays, photographs of lesions, lung function tests, walk tests, completion of questionnaires and diaries, and some genetic testing (to confirm mutation status). Reimbursement for travel may be provided.

Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.